Von Willebrand factor – Factor VIII protein-protein complex (VWF-FVIII complex)

The Von Willebrand factor – Factor VIII (VWF-FVIII) complex is a vital circulating assembly essential for normal hemostasis (UniProt P04275, P00451). Within this complex, VWF acts as a chaperone for FVIII, shielding it from proteolytic inactivation by activated protein C and preventing its rapid clearance by scavenger receptors (Lenting et al., 2007, PMID: 17381551). This stabilization is crucial, as the half-life of free FVIII is extremely short compared to the complexed form, which circulates for approximately 12-15 hours (StatPearls, NBK459215). Upon vascular injury, thrombin activates FVIII, causing it to dissociate from VWF and join the tenase complex to amplify thrombin generation (PubMed, PMID: 28637605). Pathologically, a lack of FVIII results in Hemophilia A, while defects in VWF cause Von Willebrand disease, often leading to a secondary deficiency in FVIII (NIH, Genetics Home Reference). Therapeutic interventions include replacement of the proteins or the use of engineered molecules like efanesoctocog alfa, which utilizes VWF fragments to extend the half-life of FVIII beyond the natural "VWF ceiling" (Pipe et al., 2023, PMID: 36695544). Monitoring these therapies typically involves measuring FVIII activity and VWF antigen levels in the plasma.

Other names

Factor VIII/Von Willebrand factor complexVWF-FVIII complexFVIII-VWF complexVon Willebrand factor – Factor VIII assembly

The complex functions by non-covalently binding Factor VIII to the D'D3 domains of Von Willebrand factor, which protects Factor VIII from premature degradation by activated protein C and clearance by LRP1 and other receptors, thereby extending its plasma half-life (PMID: 17381551). It also serves to transport and localize Factor VIII to sites of vascular injury where VWF binds to exposed collagen and platelets (StatPearls, NBK459215).